PL2945641T3 - Cykloalkinowe pochodne sacharydów - Google Patents
Cykloalkinowe pochodne sacharydówInfo
- Publication number
- PL2945641T3 PL2945641T3 PL14700602T PL14700602T PL2945641T3 PL 2945641 T3 PL2945641 T3 PL 2945641T3 PL 14700602 T PL14700602 T PL 14700602T PL 14700602 T PL14700602 T PL 14700602T PL 2945641 T3 PL2945641 T3 PL 2945641T3
- Authority
- PL
- Poland
- Prior art keywords
- cycloalkine
- saccharid
- derivatives
- saccharid derivatives
- cycloalkine saccharid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1300707.5A GB201300707D0 (en) | 2013-01-15 | 2013-01-15 | Compounds and processes |
| PCT/EP2014/050483 WO2014111344A1 (en) | 2013-01-15 | 2014-01-13 | Cycloalkyne derivatized saccharides |
| EP14700602.7A EP2945641B1 (en) | 2013-01-15 | 2014-01-13 | Cycloalkyne derivatized saccharides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2945641T3 true PL2945641T3 (pl) | 2020-06-15 |
Family
ID=47758014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14700602T PL2945641T3 (pl) | 2013-01-15 | 2014-01-13 | Cykloalkinowe pochodne sacharydów |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11135300B2 (pl) |
| EP (1) | EP2945641B1 (pl) |
| JP (3) | JP6719209B2 (pl) |
| CN (1) | CN105377282B (pl) |
| BR (1) | BR112015016817B1 (pl) |
| CA (1) | CA2897348C (pl) |
| CY (1) | CY1122822T1 (pl) |
| DK (1) | DK2945641T3 (pl) |
| ES (1) | ES2774729T3 (pl) |
| GB (1) | GB201300707D0 (pl) |
| HR (1) | HRP20200351T1 (pl) |
| LT (1) | LT2945641T (pl) |
| PL (1) | PL2945641T3 (pl) |
| PT (1) | PT2945641T (pl) |
| SI (1) | SI2945641T1 (pl) |
| WO (1) | WO2014111344A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201300707D0 (en) * | 2013-01-15 | 2013-02-27 | Novartis Ag | Compounds and processes |
| US20190054127A1 (en) * | 2016-03-04 | 2019-02-21 | Euglena Co., Ltd. | Antiviral agent and antiviral food |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| AU2017388891C1 (en) | 2016-12-30 | 2025-04-17 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| US12050220B2 (en) | 2018-02-05 | 2024-07-30 | University Of Miyazaki | Cell labeling agent and cell labeling kit |
| KR20250044932A (ko) | 2018-06-14 | 2025-04-01 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 가교 알긴산 |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| TW202227127A (zh) | 2020-08-19 | 2022-07-16 | 美商Ｖａｘｃｙｔｅ公司 | 載體-蛋白多醣之結合方法 |
| PH12023553205A1 (en) * | 2021-05-28 | 2024-02-19 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1490409B1 (en) | 2002-03-26 | 2008-12-31 | Novartis Vaccines and Diagnostics S.r.l. | Modified saccharides having improved stability in water |
| MX2007005202A (es) * | 2004-11-01 | 2007-07-09 | Brigham & Womens Hospital | Polisacaridos de estreptococo modificados y usos de los mismos. |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US8133515B2 (en) * | 2007-11-21 | 2012-03-13 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| ITVI20090234A1 (it) * | 2009-09-25 | 2011-03-26 | Termotecniche Fraccaro S R L Off | Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo |
| US8765920B2 (en) * | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| PL2563753T6 (pl) * | 2010-04-27 | 2016-05-31 | Synaffix Bv | Stopione związki cyklooktynu i ich zastosowanie w reakcjach typu "click" bez udziału metalu |
| WO2012017701A1 (ja) * | 2010-08-05 | 2012-02-09 | 株式会社ミュージックゲート | いびき防止マスク |
| GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| WO2012047663A2 (en) | 2010-09-27 | 2012-04-12 | University Of Georgia Reaserch Foundation, Inc. | Methods including latent 1,3-dipole-functional compounds and materials prepared thereby |
| US20120208722A1 (en) * | 2010-10-19 | 2012-08-16 | Richard Dluhy | Surface enhanced raman spectroscopy platforms and methods |
| US9550001B2 (en) * | 2011-06-20 | 2017-01-24 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
| EP2785837A4 (en) * | 2011-12-01 | 2015-07-01 | Angiochem Inc | TARGETED ENZYMATIC COMPOUNDS AND ITS USES |
| GB201300707D0 (en) * | 2013-01-15 | 2013-02-27 | Novartis Ag | Compounds and processes |
-
2013
- 2013-01-15 GB GBGB1300707.5A patent/GB201300707D0/en not_active Ceased
-
2014
- 2014-01-13 CA CA2897348A patent/CA2897348C/en active Active
- 2014-01-13 WO PCT/EP2014/050483 patent/WO2014111344A1/en not_active Ceased
- 2014-01-13 US US14/760,916 patent/US11135300B2/en active Active
- 2014-01-13 CN CN201480012960.8A patent/CN105377282B/zh active Active
- 2014-01-13 PL PL14700602T patent/PL2945641T3/pl unknown
- 2014-01-13 DK DK14700602.7T patent/DK2945641T3/da active
- 2014-01-13 JP JP2015552077A patent/JP6719209B2/ja active Active
- 2014-01-13 PT PT147006027T patent/PT2945641T/pt unknown
- 2014-01-13 BR BR112015016817-5A patent/BR112015016817B1/pt active IP Right Grant
- 2014-01-13 ES ES14700602T patent/ES2774729T3/es active Active
- 2014-01-13 LT LTEP14700602.7T patent/LT2945641T/lt unknown
- 2014-01-13 SI SI201431496T patent/SI2945641T1/sl unknown
- 2014-01-13 HR HRP20200351TT patent/HRP20200351T1/hr unknown
- 2014-01-13 EP EP14700602.7A patent/EP2945641B1/en active Active
-
2018
- 2018-12-28 JP JP2018246761A patent/JP2019073528A/ja not_active Withdrawn
-
2020
- 2020-03-13 CY CY20201100223T patent/CY1122822T1/el unknown
- 2020-03-23 JP JP2020050828A patent/JP7036854B2/ja active Active
-
2021
- 2021-05-14 US US17/320,482 patent/US12409231B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CY1122822T1 (el) | 2021-05-05 |
| HRP20200351T1 (hr) | 2020-06-12 |
| ES2774729T3 (es) | 2020-07-22 |
| JP6719209B2 (ja) | 2020-07-08 |
| EP2945641B1 (en) | 2020-01-01 |
| JP2019073528A (ja) | 2019-05-16 |
| JP2016506905A (ja) | 2016-03-07 |
| JP2020114839A (ja) | 2020-07-30 |
| WO2014111344A1 (en) | 2014-07-24 |
| US12409231B2 (en) | 2025-09-09 |
| CN105377282A (zh) | 2016-03-02 |
| BR112015016817A8 (pt) | 2019-10-29 |
| SI2945641T1 (sl) | 2020-03-31 |
| JP7036854B2 (ja) | 2022-03-15 |
| CA2897348A1 (en) | 2014-07-24 |
| US20160166704A1 (en) | 2016-06-16 |
| PT2945641T (pt) | 2020-03-26 |
| LT2945641T (lt) | 2020-02-25 |
| CN105377282B (zh) | 2020-07-17 |
| US20210268116A1 (en) | 2021-09-02 |
| US11135300B2 (en) | 2021-10-05 |
| BR112015016817B1 (pt) | 2020-11-10 |
| BR112015016817A2 (pt) | 2017-07-11 |
| CA2897348C (en) | 2022-09-27 |
| GB201300707D0 (en) | 2013-02-27 |
| DK2945641T3 (da) | 2020-03-09 |
| EP2945641A1 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301272I2 (nl) | Fezolinetant | |
| NL301247I2 (nl) | mirikizumab | |
| FIC20210025I1 (fi) | Lumasiraani | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3613453T3 (da) | Fordamper | |
| DK3052081T3 (da) | Pastil | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| DK2956698T5 (da) | Bindestrimler | |
| DK2952513T3 (da) | Azolbenzenderivat | |
| PL2945641T3 (pl) | Cykloalkinowe pochodne sacharydów | |
| DK2946640T3 (da) | Langmuir-probe | |
| EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| NL301170I2 (nl) | Somatrogon | |
| EP2991647A4 (en) | DEUTERED AMLEXANOX | |
| EP2970310A4 (en) | 5-BROMO-indirubins | |
| EP2853297A4 (en) | kendama | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK3086679T3 (da) | Sportssko | |
| DK2981168T3 (da) | Laminitiskile | |
| EP3009444A4 (en) | ALPHA-oxoacyl-Amino-caprolactam derivative | |
| FR3008292B1 (fr) | Perloir | |
| ES1078715Y (es) | Mosquitera |